INTRODUCTION
============

The clinical manifestation of Crohn's disease (CD) is heterogeneous, and the natural course is unpredictable, with phenotypic changes over time.[@b1-gnl-10-595]--[@b5-gnl-10-595] The development of prognostic markers would enable early treatment for severe CD. Although several clinical indices and serological and fecal markers, such as calprotectin, and genetic biomarkers, such as nucleotide-binding oligomerization domain-containing protein 2, have been evaluated for the prediction of clinical course, a definitive predictive marker has not been fully established.[@b6-gnl-10-595]--[@b10-gnl-10-595]

C-reactive protein (CRP) is a surrogate marker of acute inflammation induced by infection, stress, tissue necrosis, trauma, and malignancies.[@b11-gnl-10-595] CRP is synthesized principally by hepatocytes in response to stimulation by interleukin-1, interleukin-6 (IL-6), and tumor necrosis factor-α (TNF-α).[@b12-gnl-10-595] Recent studies have suggested that CRP is also produced by peripheral lymphocytes, inflamed kidneys, alveolar macrophage, and adipocytes in quantities insufficient to affect plasma CRP levels.[@b13-gnl-10-595],[@b14-gnl-10-595] CRP functions independent of physiological and pathological conditions and plasma CRP levels in patients with CD.[@b11-gnl-10-595] Therefore, CRP production by the liver may be the only factor determining the plasma CRP level, suggesting the potential of CRP as a valuable marker to diagnose and monitor CD patients.

Estimating CRP may be useful to evaluate disease activity because it requires an inexpensive and easily accessible test; in addition, compared to other inflammatory markers, CRP has a short half-life of 19 hours.[@b15-gnl-10-595] Several studies have demonstrated that CRP levels are associated with the clinical, radiographic, endoscopic, and histological activity in CD.[@b16-gnl-10-595]--[@b18-gnl-10-595] However, whether CRP levels can predict the clinical course is not known. Higher CRP levels at the time of diagnosis or relapse have been associated with more frequent and severe short- and medium-term relapses.[@b11-gnl-10-595],[@b19-gnl-10-595] A retrospective study from Portugal reported that high CRP in CD predicts nonresponse to infliximab.[@b20-gnl-10-595] However, these data were from a single-center study with a small number of subjects, thus limiting the generalizability of the results. There is lack of reports that provide conclusive evidence for predicting aggressive clinical course and establishing treatment plan.

We therefore conducted a multicenter cohort study of a large number of CD subjects to determine if the CRP level at diagnosis is a valuable predictive marker of disease phenotype, activity, and clinical course.

MATERIALS AND METHODS
=====================

1. Study population
-------------------

We reviewed a retrospective clinical database that included patients diagnosed with CD between July 1982 and December 2008 who were enrolled in the Crohn's Disease Clinical Network and Cohort (CONNECT) study. The gastroenterology clinics of 32 institutions in Korea participated in this cohort study, which was performed by the Korean Association for the Study of Intestinal Diseases.[@b21-gnl-10-595],[@b22-gnl-10-595] The institutions comprised 30 university hospitals and two community hospitals. Patients were eligible for the study if they had a measurable CRP level at the time of diagnosis, they did not have coexisting infectious colitis, they were followed up for longer than 6 months (to identify long-term clinical outcomes), and the status of their CD was evaluated before enrollment and at the end of the study. We excluded patients with incomplete clinical data (n=100), those for whom CRP level at diagnosis was unavailable (n=490), and those with lack of medical record from the referral hospitals (n=79), and those who were followed up for less than 6 months (n=8).

Patients were classified into two groups based on CRP \>20 mg/L and ≤20 mg/L.

The diagnosis of CD was confirmed in all cases by previously established guidelines based on clinical history, endoscopic and radiological examinations, and histopathological findings.[@b23-gnl-10-595]

2. Data collection and outcome measurement
------------------------------------------

Clinical data at initial presentation of CD and subsequent follow-up visits were retrieved for analysis from the electronic medical record system. The collected data included age, gender, length of follow-up, disease location, and behavior at the time of diagnosis according to the Montreal classification. Disease location at final follow-up was categorized as colorectum, jejunum, ileum, or esophagogastroduodenum. The development of intestinal strictures, perianal fistula, and other fistulas and the time required to develop these lesions were assessed. Other fistulas were defined as abnormal tracks formed between the gut and gut, skin, an abscess cavity, or other hollow structures including the bladder, urethra, uterus, or vagina. We also recorded complications including abscesses, perforations, intestinal cancers, and primary sclerosing cholangitis.

Clinical disease activity at the time of diagnosis was assessed using the Crohn's disease activity index (CDAI), with a score of \>150 indicating active disease. Among the typical endoscopic features of CD, a cobblestone appearance and longitudinal ulcers were reviewed because these lesions can indicate increased CD activity. We recorded medication use during follow-up period, including 5-aminosalicylic acid (5-ASA), antibiotics, budesonide, and corticosteroids. The use of immunosuppressants, including azathioprine, 6-mercaptopurine, methotrexate, and TNF blockers such as infliximab and adalimumab, was also reviewed. Time from CD diagnosis to first use of azathioprine or TNF blockers was calculated to assess the length of time before these drugs were required to treat severe disease. Disease-related hospitalization (including readmissions) and surgery data were assessed because these can indicate a more severe course in CD.[@b24-gnl-10-595] The collected data regarding hospitalization included the total number of hospital admissions and the readmission rate. In this analysis, readmission was defined as two or more admission of a discharged patient for further inpatient care as a new episode.

The proportion of patients who underwent surgery was recorded, and additional data including the total number of surgeries, resurgeries, and survival rates were obtained. These patients were analyzed according to the causative lesion for surgery or resurgery: intestinal or perianal lesion. Resurgery was defined as surgery at the same lesion site or at another site for a relapsed or uncontrolled lesion or to repair temporary structures from a previous surgery such as ileostomy repair. This study protocol was reviewed and approved by the Institutional Review Board of each participating medical center.

3. Statistical analysis
-----------------------

Continuous variables are presented as means±standard deviation when appropriate. Categorical variables were summarized as frequency and percentage. We performed univariate analyses using an independent t-test for continuous variables and the Pearson chi-square test, Fischer exact test, or linear by linear association for categorical variables. Kaplan-Meier method and log-rank test were used to determine the cumulative probability of stricture, perianal fistula, other fistula, use of azathioprine and TNF blocker, and risk of surgery according to the CRP level at diagnosis. Binary logistic regression analysis was performed using a forward stepwise selection method to evaluate risk factors affecting hospital admission of patients with CD. A multivariate analysis was performed if the univariate analysis yielded p\<0.25. A p-value \<0.05 was considered to indicate statistical significance. All analyses were performed using IBM SPSS version 20.0 (IBM Corp., Armonk, NY, USA).

RESULTS
=======

1. Demographic and clinical characteristics of patients
-------------------------------------------------------

A total of 705 CD patients with measurable CRP levels were ultimately included in this analysis. The CRP value at the time of diagnosis was used as the index CRP level. The patients were classified into two groups by their index CRP level, with a cutoff at 20 mg/L: 373 had a CRP \>20, and 332 had a CRP ≤20 mg/L. The patients were 7 to 77 years of age at the time of CD diagnosis, and the mean follow-up duration was 7.1 years. The demographic, clinical and laboratory details of the two groups are summarized in [Table 1](#t1-gnl-10-595){ref-type="table"}. There were no significant differences between the groups in gender, family history of inflammatory bowel disease (IBD), history of perianal disease, or history of taking anti-tuberculosis medications. Body mass index (BMI) was significantly lower in the high CRP group. Patients with high CRP were younger at diagnosis than those with low CRP (p\<0.001) and had lower hemoglobin, higher CDAI, and elevated erythrocyte sedimentation rate (ESR). There was a significant difference in lesion location at time of diagnosis (p\<0.001). Lesions in the high CRP group more frequently involved the colon (24.4%) and ileocolon (56.4%), while the low CRP group had more frequent terminal ileal (32.9%) and ileocolonic (48.4%) involvement. The CRP level did not distinguish disease behavior (p=0.503); the nonstricturing and nonpenetrating phenotype (B1) was the most frequent disease behavior type in both groups. Location and behavior at diagnosis were unavailable in 137 and 192 patients, respectively. Corticosteroid use at the time of diagnosis was significantly higher in the high CRP group compared with the low CRP group (41.2% vs 25.3%, p\<0.001).

2. Disease manifestation
------------------------

Colorectal involvement during the course of the disease was more frequent in the high CRP group (p\<0.001). There were no statistically significant differences in jejunal, ileal, and esophagogastroduodenal involvement between the two groups. Endoscopic findings of longitudinal ulcer and cobblestone appearance were more frequent in the high CRP group (p\<0.001 and p\<0.001, respectively). Stricture during the course of the disease was more frequent in the high compared to the low CRP group (p=0.027). There were no significant differences in the development of fistulas, intestinal perforations, abscesses, intestinal cancers, or primary sclerosing cholangitis between the groups ([Table 2](#t2-gnl-10-595){ref-type="table"}). Using the Kaplan-Meier method, significant difference was found in the cumulative probability of stricture according to the CRP level at diagnosis (p=0.019). However, cumulative probability of perianal fistula and other fistula did not differ ([Fig. 1](#f1-gnl-10-595){ref-type="fig"}).

3. Use of medications
---------------------

Medication use was investigated according to the index CRP level ([Table 3](#t3-gnl-10-595){ref-type="table"}). There were significant differences between the two groups in the use of 5-ASA-based agents, antibiotics, corticosteroids, azathioprine, and biological agents (p\<0.001, p\<0.001, p\<0.001, p\<0.001, and p=0.042, respectively). Of these medications, more subjects with high CRP had used infliximab (p=0.023), but there was no significant difference in adalimumab use between the two groups. The cumulative use of azathioprine and TNF blocker was significantly higher in high CRP group than in low CRP group ([Fig. 2](#f2-gnl-10-595){ref-type="fig"}).

4. Hospital admission, surgery, and survival
--------------------------------------------

The total numbers of hospital admissions and readmissions were also analyzed according to the index CRP level. The total number of hospital admissions differed significantly between the patients with high or low CRP (3.2±4.2 vs 2.3±3.7, p=0.011). In addition, the rate of readmission was higher in the high CRP group (p=0.048). Regarding CD-related surgeries, there were no significant differences in the total number of surgeries or the proportion of patients who underwent surgery for intestinal or perianal lesions between the two groups, nor did they differ in the proportion of repeat surgeries for intestinal or perianal lesions. The cumulative risk of surgery and resurgery did not differ according to the CRP level at diagnosis ([Fig. 2](#f2-gnl-10-595){ref-type="fig"}). Only two patients died during the follow-up period: one from cardiac arrest of unknown cause and the other from intestinal bleeding associated with CD ([Table 4](#t4-gnl-10-595){ref-type="table"}).

5. Predictors of hospitalization
--------------------------------

We performed logistic regression analysis to identify factors that predicted hospitalization ([Table 5](#t5-gnl-10-595){ref-type="table"}). In univariate analysis, high index CRP, younger age, use of a TNF blocker, high CDAI at diagnosis, and a stricturing phenotype were all significant risk factors for hospitalization. Variables including high CRP (hazard ratio \[HR\], 2.03; 95% confidence interval \[CI\], 1.10 to 3.82; p=0.028), use of a TNF blocker (HR, 22.90; 95% CI, 3.10 to 172.10; p=0.002), and a stricturing phenotype (HR, 11.31; 95% CI, 2.62 to 48.81; p=0.001) were also significant risk factors for hospitalization in the multivariate analysis.

DISCUSSION
==========

In this study, CD patients with CRP \>20 mg/L were more likely to be younger and exhibit colonic or ileocolonic involvement. The CRP level was a useful index of clinical and endoscopic disease activity. During follow-up, high CRP was associated with more aggressive treatments, such as immunosuppressants and biological agents, and with the total number of hospital admissions and readmissions.

CRP was described as a marker for the differential diagnosis of CD and ulcerative colitis,[@b15-gnl-10-595] and the association between CRP and disease activity has been investigated. Several recent studies have reported a correlation between the index CRP and clinical relapses, the subsequent need for aggressive treatment, and response to treatment.[@b19-gnl-10-595],[@b25-gnl-10-595] However, research supporting the CRP level at the time of diagnosis as a predictor of the clinical course is lacking.

In a recent study by the Brisbane IBD research group, the low CRP group had a strikingly lower BMI and more pure ileal disease (predisposing them to intestinal resections) than the high CRP group.[@b26-gnl-10-595] A retrospective study in Germany also reported disease with an exclusively ileal distribution in the low CRP group.[@b27-gnl-10-595] Although we could not reproduce the correlation between a low BMI and prior intestinal resection, we confirmed that patients with low CRP tend to develop ileal disease, while those with high CRP have a higher frequency of colonic involvement. Our results are consistent with those of previous studies.[@b16-gnl-10-595],[@b18-gnl-10-595],[@b28-gnl-10-595] Although the exact mechanism underlying the predominance of ileal lesions in the low CRP group is not understood, a study has indicated that ileal disease has a tendency to evolve more locoregional inflammatory disease, as evidenced by a high rate of fat wrapping in surgical specimens, than systemic disease and, consequently, does not elevate CRP.[@b26-gnl-10-595]

Studies of the Montreal classification of CD behavior based on the CRP level have yielded conflicting results. In a prospective population-based study, noninflammatory behavior including stricturing or penetrating disease was associated with a high CRP at the time of diagnosis.[@b25-gnl-10-595] By contrast, a retrospective database-based study concluded that there was no significant difference in disease behavior based on the index CRP level during a clinical relapse.[@b19-gnl-10-595] However, little information is available regarding changes in disease behavior during the course of the disease among these patients. In our study, there was no significant difference in disease behavior between the two groups at the initial presentation of CD, and inflammatory disease was the predominant phenotype in both groups. In addition, we found that intestinal strictures occurred more frequently in high CRP patients throughout the disease course. Our findings suggest that high CRP patients have a higher likelihood of fibrostenotic changes because they have a chronic inflammatory profile. We therefore believe that CRP can be a valuable tool to predict further stricture formation, which is a major indication for surgery.

We also observed that high CRP was significantly correlated with a cobblestone appearance and longitudinal ulcers at colonoscopy, which suggest active inflammation. In addition, the CDAI score of high CRP patients was higher than the score of those with low CRP. These results correspond with those of a retrospective study of 147 American patients that demonstrated that an elevated CRP was associated with clinical disease activity, endoscopic inflammation, and several other IBD biomarkers.[@b16-gnl-10-595]

CRP can be used to predict subsequent need for azathioprine and biological agents as well as clinical relapse.[@b19-gnl-10-595] A retrospective study in the Netherlands provided additional evidence for the role of CRP in predicting a more severe clinical course of CD, such as number of relapses, severity of relapse, and cumulative days of prednisone use.[@b25-gnl-10-595] In accord with previous studies, we determined that patients with high CRP received more aggressive medical treatment, such as immunosuppressants or biological agents. Our multivariate analysis also indicated that a high CRP level is an independent predictor for hospitalization. Interestingly, the CRP groups did not differ in their need for surgery or repeat surgery. These results coincide well with those of a previous study that reported that patients with low CRP more often have purely ileal disease, with an increased requirement for intestinal resection.[@b26-gnl-10-595] Accordingly, we can postulate that the surgery rate in patients with low CRP would be similar to that of those with a high CRP, in whom more aggressive treatment would be required.

In the present study, we observed a correlation of CRP levels with clinical progression to severe disease. Although the precise mechanisms underlying this correlation have not been fully elucidated, some plausible explanation for these results can be inferred from some published reports. Mesenteric fat, rather than the intestinal wall, is likely important for the production of CRP in CD patients.[@b29-gnl-10-595] The mesenteric fat hyperplasia observed in CD but not UC has been suggested to contribute to the synthesis of inflammatory mediators such as TNF-α and IL-6, which promote damage to the intestinal mucosa. In addition, mesenteric fat hyperplasia could impair gut barrier function by disturbing innate immunity to the gut flora.[@b30-gnl-10-595] Based on these findings, the elevation of CRP at baseline could reflect the degree of mesenteric fat hyperplasia. Accordingly, increased production of inflammatory cytokines via the accumulation of mesenteric adipocytes might induce a severe, ongoing, inflammatory process, and direct assessment of this inflammatory activity could facilitate the prediction of a more severe clinical course.

Several studies have presented different CRP cutoff values for CD patients,[@b19-gnl-10-595],[@b25-gnl-10-595],[@b31-gnl-10-595] but a definitive cutoff value for predicting disease activity and clinical course has not been established. In a study of French patients, high CRP (\>20 mg/L) was emphasized as a valuable diagnostic marker for predicting a van Hees index ≥150.[@b32-gnl-10-595] The GETAID group emphasized that CRP \>20 mg/L and ESR \>15 mm/hr were the only meaningful laboratory markers predictive of relapse.[@b31-gnl-10-595] Furthermore, a multicenter randomized controlled study indicated that high CRP (\>20 mg/L) was correlated with relapse after azathioprine withdrawal.[@b33-gnl-10-595] These results determined our selection of 20 mg/L as the optimal CRP cutoff value for categorizing the disease manifestations and clinical course of CD.

This study improves upon previous studies by employing a multicenter cohort from 32 institutions of CD patients with measurable CRP. This design minimizes bias that might arise from a single center case-control study. We also enrolled a significant proportion of potential cases, ultimately including 705 patients and thereby substantially increasing the statistical power. Furthermore, uniform findings based on the CRP level were reproduced in this study despite the heterogeneity of the studied population. The classification of disease phenotype, activity and clinical course by CRP level may therefore be applicable to the patients with CD in clinical practice.

Our study is limited by its retrospective nature, which limits our ability to provide a causal explanation for the relationship between CRP levels and clinical outcomes.

This study includes missing values on potentially important covariates, which could be unavoidable in retrospective and observational study. However, unavailable data is mostly due to insufficient data collection and work-up or loss to follow-up before electronic medical record was introduced in the early 2000s. In addition, there is a possibility of poor quality assurance concerning admission, treatment, and follow-up and patient enrollment with relatively severe disease state due to characteristics of participating secondary or tertiary care center, which could limit reliability of the study. However, these potential confounders were minimized by the retrieval of clinical data from electronic medical record systems at all participating hospitals and accurate recording of the time to occurrence of any event or use of medication. Unfortunately, we could not investigate clinical data on the frequency or severity of relapses, improvement of subjective symptoms, and treatment response, particularly for biological agents, due to the lack of medical records and the observational study design. In conclusion, CRP at the time of diagnosis appears to be useful in predicting disease phenotype, clinical and endoscopic activity, and the clinical course of CD. Early aggressive treatment with intensive follow-up management strategy may be warranted in patients with high CRP. In addition, the integration of CRP levels with other predictive indices will improve the reliability of the identification of the natural history of CD. A further prospective study that includes a large number of subjects could provide definitive evidence of the correlation of CRP levels with multiple clinical outcomes.
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![(A) Kaplan-Meier curve showing the cumulative probability of stricture according to the C-reactive protein (CRP) level (log-rank test, p=0.019). (B) Kaplan-Meier curve showing the cumulative probability of perianal fistula according to the CRP level (log-rank test, p=0.157). (C) Kaplan-Meier curve showing the cumulative probability of other fistula according to the CRP level (log-rank test, p=0.086).](gnl-10-595f1){#f1-gnl-10-595}

![(A) Kaplan-Meier curve showing the cumulative use of azathioprine according to the C-reactive protein (CRP) level (log-rank test, p\<0.001). (B) Kaplan-Meier curve showing the cumulative use of a tumor necrosis factor blocker according to the CRP level (log-rank test, p=0.041). (C) Kaplan-Meier curve showing cumulative risk of surgery according to the CRP level (log-rank test, p=0.067). (D) Kaplan-Meier curve showing cumulative risk of resurgery according to the CRP level (log-rank test, p=0.489).](gnl-10-595f2){#f2-gnl-10-595}

###### 

Baseline Characteristics of Patients with Crohn's Disease according to the C-Reactive Protein Level at Diagnosis

  Variable                                                           CRP \>20 (n=373)   CRP ≤20 (n=332)   p-value
  ------------------------------------------------------------------ ------------------ ----------------- ---------
  Age, yr                                                            25.4±10.1          28.6±14.2         \<0.001
  Sex, male/female                                                   285/88             238/94            0.153
  Time to follow-up, mo                                              86.4±44.1          83.5±43.9         0.379
  BMI, kg/m^2^                                                       19.1±3.3           20.9±4.2          \<0.001
  Smoking status                                                                                          0.020
   Never smoker                                                      245 (77.8)         168 (70.0)        
   Current smoker                                                    46 (14.6)          36 (15.0)         
   Ex-smoker                                                         16 (5.1)           31 (12.9)         
   Stop smoking after treatment                                      8 (2.5)            5 (2.1)           
  Family history of IBD                                              9 (2.4)            7 (2.1)           0.447
  Hb, g/dL                                                           11.9±1.9           12.8±2.1          \<0.001
  Hct, %                                                             36.0               38.1              \<0.001
  ESR, mm/hr                                                         47.5±29.2          23.6±21.5         \<0.001
  CDAI at diagnosis                                                  217.5±110.2        164.6±89.2        \<0.001
  Location at diagnosis[\*](#tfn3-gnl-10-595){ref-type="table-fn"}                                        \<0.001
   L1 (ileal)                                                        51 (17.5)          91 (32.9)         
   L2 (colonic)                                                      71 (24.4)          48 (17.3)         
   L3 (ileocolonic)                                                  164 (56.4)         134 (48.4)        
   L4 (upper GI)                                                     5 (1.7)            4 (1.4)           
  Behavior at diagnosis[\*](#tfn3-gnl-10-595){ref-type="table-fn"}                                        0.503
   B1 (inflammatory)                                                 176 (71.3)         193 (72.6)        
   B2 (stricturing)                                                  32 (13.0)          39 (14.7)         
   B3 (penetrating)                                                  39 (15.8)          34 (12.8)         
  Steroid use at diagnosis                                           154 (41.2)         84 (25.3)         \<0.001
  History of anti-TB medication                                      67 (18.0)          70 (21.1)         0.296
  History of perianal disease                                        108 (29.0)         81 (24.4)         0.173

Data are presented as mean±SD or number (%).

CRP, C-reactive protein; BMI, body mass index; IBD, inflammatory bowel disease; Hb, hemoglobin; Hct, hematocrit; ESR, erythrocyte sedimentation rate; CDAI, Crohn's disease activity index; GI, gastrointestinal; TB, tuberculosis.

Location and behavior at the time of diagnosis were unavailable in 137 and 192 patients, respectively.

###### 

Disease Manifestation according to the C-Reactive Protein Level at Diagnosis

  Variable                                                       CRP \>20 (n=373)   CRP ≤20 (n=332)   p-value
  -------------------------------------------------------------- ------------------ ----------------- ---------
  Involved location                                                                                   
   Colorectum                                                    322 (86.3)         222 (66.9)        \<0.001
   Jejunum                                                       49 (13.1)          61 (18.4)         0.651
   Ileum                                                         310 (83.1)         270 (81.3)        0.917
   Esophagogastroduodenum                                        36 (9.7)           27 (8.1)          0.324
  Endoscopic findings                                                                                 
   Longitudinal ulcer                                            255 (68.4)         148 (44.6)        \<0.001
   Cobblestone appearance                                        160 (42.9)         57 (17.2)         \<0.001
  Histological finding                                                                                
   Granuloma                                                     148 (39.7)         110 (33.1)        0.657
  Stricture                                                                                           0.027
   Yes, at diagnosis                                             49 (13.5)          33 (10.0)         
   Yes, during disease course                                    46 (12.7)          29 (8.8)          
  Perianal fistula                                                                                    0.137
   Yes, at diagnosis                                             105 (28.6)         77 (23.3)         
   Yes, during disease course                                    35 (9.5)           28 (8.5)          
  Other fistula                                                                                       0.145
   Yes, at diagnosis                                             27 (7.4)           10 (3.1)          
   Yes, during disease course                                    28 (7.7)           22 (6.7)          
  Abdominal abscess                                                                                   0.068
   Yes, at diagnosis                                             20 (5.5)           14 (4.3)          
   Yes, during disease course                                    31 (8.5)           17 (5.3)          
  Perforation                                                                                         0.103
   Yes, at diagnosis                                             14 (3.8)           14 (4.3)          
   Yes, during disease course                                    6 (1.6)            12 (3.7)          
  Intestinal cancer[\*](#tfn6-gnl-10-595){ref-type="table-fn"}                                        0.659
   Yes, at diagnosis                                             1 (0.3)            3 (0.9)           
   Yes, during disease course                                    2 (0.5)            0                 
  Primary sclerosing cholangitis                                                                      0.472
   No                                                            364 (100)          324 (99.7)        
   Yes, during disease course                                    0                  1 (0.3)           

Data are presented as number (%).

CRP, C-reactive protein.

Includes small bowel and colon cancer.

###### 

Use of Medications according to the C-Reactive Protein Level at Diagnosis

  Variable                          CRP \>20 (n=373)   CRP ≤20 (n=332)   p-value
  --------------------------------- ------------------ ----------------- ---------
  Use of medications                                                     
   5-ASA                            368 (98.7)         309 (93.1)        \<0.001
   Antibiotics                      239 (64.1)         153 (46.1)        \<0.001
   Budesonide                       42 (11.3)          32 (9.6)          0.494
   Corticosteroid                   263 (70.5)         164 (49.7)        \<0.001
   Azathioprine                     281 (75.3)         194 (58.4)        \<0.001
   MTX                              4 (1.1)            6 (1.8)           0.407
   Infliximab                       102 (27.4)         66 (19.9)         0.023
   Adalimumab                       21 (5.6)           15 (4.5)          0.516
   TNF blocker                      111 (29.8)         76 (22.9)         0.042
  TPN                               77 (20.6)          59 (17.8)         0.796
  Time to use of azathioprine, mo   28.8±34.0          28.6±31.3         0.950
  Time to use of TNF blockers, mo   52.2±41.1          61.8±43.1         0.114

Data are presented as number (%) or mean±SD.

CRP, C-reactive protein; ASA, aminosalicylic acid; MTX, methotrexate; TNF, tumor necrosis factor; TPN, total parenteral nutrition.

###### 

Hospital Admission, Surgery, and Survival according to the C-Reactive Protein Level at Diagnosis

  Variable                         CRP \>20 (n=373)   CRP ≤20 (n=332)   p-value
  -------------------------------- ------------------ ----------------- ---------
  Total no. of admission           3.10±4.20          2.30±3.70         0.011
  Readmission                      193 (51.7)         147 (44.3)        0.048
  Patients performed surgery       179 (48.0)         146 (44.0)        0.286
  Total no. of surgeries           1.50±0.84          1.50±0.81         0.823
  Surgery of intestinal lesion     82 (22.0)          74 (22.3)         0.922
  Surgery of perianal lesion       109 (29.2)         76 (22.9)         0.056
  Resurgery of intestinal lesion   15 (4.0)           9 (2.7)           0.338
  Resurgery of perianal lesion     26 (7.0)           25 (7.5)          0.775
  Dead                             1 (0.3)            1 (0.3)           0.932

Data are presented as mean±SD or number (%).

CRP, C-reactive protein.

###### 

Multivariate Logistic Regression Analysis to Evaluate Potential Predictors for Hospitalization

  Variable                Univariate analysis   Multivariate analysis                                    
  ----------------------- --------------------- ----------------------- --------- ------- -------------- -------
  CRP, \>20 mg/L          2.30                  1.63--3.26              \<0.001   2.03    1.10--3.82     0.028
  Age                     0.98                  0.97--0.99              0.004     0.99    0.97--1.02     0.761
  Use of TNF blocker      7.16                  3.88--13.23             \<0.001   22.90   3.10--172.10   0.002
  CDAI at diagnosis       1.00                  1.00--1.01              0.021     1.00    1.00--1.01     0.255
  Stricturing phenotype   3.86                  2.23--6.69              \<0.001   11.31   2.62--48.81    0.001

HR, hazard ratio; CI, confidence interval; CRP, C-reactive protein; TNF, tumor necrosis factor; CDAI, Crohn's disease activity index.
